Indegene launched the strategic acquisition of BioPharm, a Pennsylvania-based specialized marketing services agency and part of Omnicom Health Group.
This initiative by ILSL Inc., a subsidiary of Indegene Limited, strengthens Indegene’s commercialization portfolio with AdTech, combining AI and digital advertising, enabling pharma companies to drive more precise, scalable, and measurable outcomes and this solidifies Indegene’s position as a true category leader in data-driven Omnichannel and Media Space.
According to Coherent Market Insights, the Pharmaceutical Market is projected to grow at a CAGR of 8.1% during 2025 to 2032. Currently, the market is at USD 1.81 Tillion in 2025 and is expected to be around USD 3.12 Tillion by 2032. This significant growth trajectory is driven by the rising healthcare demands, advancements in drug development, and increasing investments in biopharmaceutical research worldwide, positioning the market for robust expansion over the forecast period.
“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialization partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments”, said Manish Gupta, Chairman and CEO, Indegene. “I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialization together.”
“Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture – backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. And, we are very excited to join the larger Indegene family at a pivotal time for the industry”, said Steve Carickhoff, President, BioPharm. “Their life sciences-contextualized approach to AI will open up new possibilities, helping us deliver deeper value to clients. Together, we will push the boundaries of AI-powered pharma marketing worldwide – delivering more personalized, measurable, and patient-focused outcomes.”
The acquisition by Indegene is especially significant as many pharma companies have the twin agendas of managing mature and growth product portfolios and ramping up capabilities for new launches in an environment where physicians increasingly favor limited engagement models. These imperatives, along with the productivity agenda, are driving the adoption of innovative digital engagement approaches.
This strong initiative of Indegene and BioPharm brings together vast, rich data assets that will drive significantly higher Media ROI and enable more effective Agentic Operations.
Source:
News: Indegene
Company: Indegene
